Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.

Hdl Handle:
http://hdl.handle.net/10144/204590
Title:
Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.
Authors:
Ritmeijer, Koert; ter Horst, Rachel; Chane, Solomon; Aderie, Endashaw Mengistu; Piening, Turid; Collin, Simon M; Davidson, Robert N
Journal:
Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of America
Abstract:
Due to unacceptably high mortality with pentavalent antimonials, Médecins Sans Frontières in 2006 began using liposomal amphotericin B (AmBisome) for visceral leishmaniasis (VL) patients in Ethiopia who were severely ill or positive for human immunodeficiency virus (HIV).
Affiliation:
Public Health Department, Médecins Sans Frontières, Amsterdam, the Netherlands. koert.ritmeijer@amsterdam.msf.org
Issue Date:
Dec-2011
URI:
http://hdl.handle.net/10144/204590
DOI:
10.1093/cid/cir674
PubMed ID:
22016502
Language:
en
ISSN:
1537-6591
Appears in Collections:
Other Diseases

Full metadata record

DC FieldValue Language
dc.contributor.authorRitmeijer, Koerten
dc.contributor.authorter Horst, Rachelen
dc.contributor.authorChane, Solomonen
dc.contributor.authorAderie, Endashaw Mengistuen
dc.contributor.authorPiening, Turiden
dc.contributor.authorCollin, Simon Men
dc.contributor.authorDavidson, Robert Nen
dc.date.accessioned2012-01-24T23:34:29Z-
dc.date.available2012-01-24T23:34:29Z-
dc.date.issued2011-12-
dc.identifier.citationLimited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. 2011, 53 (12):e152-8 Clin. Infect. Dis.en
dc.identifier.issn1537-6591-
dc.identifier.pmid22016502-
dc.identifier.doi10.1093/cid/cir674-
dc.identifier.urihttp://hdl.handle.net/10144/204590-
dc.description.abstractDue to unacceptably high mortality with pentavalent antimonials, Médecins Sans Frontières in 2006 began using liposomal amphotericin B (AmBisome) for visceral leishmaniasis (VL) patients in Ethiopia who were severely ill or positive for human immunodeficiency virus (HIV).en
dc.language.isoenen
dc.rightsPublished by: Infectious Diseases Society of America and University of Chicago Press Archived on this site with permission and copyright 2011 by the Infectious Diseases Society of Americaen
dc.titleLimited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.en
dc.contributor.departmentPublic Health Department, Médecins Sans Frontières, Amsterdam, the Netherlands. koert.ritmeijer@amsterdam.msf.orgen
dc.identifier.journalClinical Infectious Diseases : an official publication of the Infectious Diseases Society of Americaen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.